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http://www.neuraldevelopment.com/content/9/1/6RESEARCH ARTICLE Open AccessMultiple conserved regulatory domains promote
Fezf2 expression in the developing cerebral
cortex
Matthew J Eckler1, Kathryn A Larkin1†, William L McKenna1†, Sol Katzman2, Chao Guo1, Robin Roque1, Axel Visel3,4,
John L R Rubenstein5 and Bin Chen1*Abstract
Background: The genetic programs required for development of the cerebral cortex are under intense
investigation. However, non-coding DNA elements that control the expression of developmentally important genes
remain poorly defined. Here we investigate the regulation of Fezf2, a transcription factor that is necessary for the
generation of deep-layer cortical projection neurons.
Results: Using a combination of chromatin immunoprecipitation followed by high throughput sequencing
(ChIP-seq) we mapped the binding of four deep-layer-enriched transcription factors previously shown to be important
for cortical development. Building upon this we characterized the activity of three regulatory regions around the Fezf2
locus at multiple stages throughout corticogenesis. We identified a promoter that was sufficient for expression in the
cerebral cortex, and enhancers that drove reporter gene expression in distinct forebrain domains, including progenitor
cells and cortical projection neurons.
Conclusions: These results provide insight into the regulatory logic controlling Fezf2 expression and further the
understanding of how multiple non-coding regulatory domains can collaborate to control gene expression in vivo.
Keywords: Fezf2, Enhancer, Promoter, Cerebral cortex, Gene regulation, TranscriptionBackground
Current estimates suggest that greater than half of evolu-
tionarily conserved sequences in the human genome do
not correspond to protein coding regions [1-4]. Transcrip-
tional enhancers, non-coding DNA sequences that pro-
mote gene expression in a spatial and temporal manner,
constitute a substantial portion of these regions [5].
Genome-wide association studies (GWAS) have identified
sequence variations within putative enhancers that are as-
sociated with a wide range of neurological disorders such
as autism, epilepsy, and schizophrenia [6-10]. However,
the function of these DNA elements during normal brain
development remains poorly understood [11].
The cerebral cortex contains six layers of projection
neurons that are generated in a stereotyped manner such* Correspondence: bchen@ucsc.edu
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unless otherwise stated.that deep-layer neurons, layers 5 and 6 (L5 and L6), are
born before upper-layer neurons [12]. It has previously
been shown that the transcription factor Fezf2 is necessary
and sufficient for the generation of deep-layer subcerebral
projection neurons (SCPNs) [13-16]. Collectively, these
studies suggest that Fezf2 functions high in a transcrip-
tional hierarchy that regulates SCPN development and
fate specification [14,17-19]. Despite the essential role of
Fezf2 in neural development, little is known about how its
transcription is precisely regulated.
To investigate the regulatory mechanisms controlling
Fezf2 transcription, we utilized chromatin immunopre-
cipitation combined with high throughput DNA sequen-
cing (ChIP-seq) to identify a transcription factor-binding
signature around the Fezf2 locus. Guided by our ChIP-
seq data, we mapped a promoter that was sufficient for
reporter gene expression in the cerebral cortex through-
out cortical development, and investigated the activity of
two putative Fezf2 enhancers. We demonstrate that atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion in cortical progenitor cells while a putative up-
stream enhancer, 1316, is strictly active in deep-layer
neurons within the cortex. Taken together, these results
provide insight into the developmental programs that
promote Fezf2 expression during development of the
cerebral cortex.
Results
Fezf2 is dynamically expressed during development of
the cerebral cortex
Towards understanding how Fezf2 transcription is regu-
lated, we first examined its expression during cortical
neurogenesis (Figure 1A-C’). Consistent with previous re-
ports [20,21], at E12.5 Fezf2 expression was detected in
ventricular zone (VZ) progenitors and deep-layer cortical
neurons (Figure 1A-A’). At E15.5 Fezf2 expression began
to decline in L6, but remained high in L5 (Figure 1B-B’).
Expression at P0 was similar to E15.5 (Figure 1C-C’).
Thus, at late stages of cortical development, expression of
Fezf2 in the cerebral cortex was restricted to three distinct
domains: higher expression in L5 neurons, and lower ex-
pression in L6 neurons and progenitors (Figure 1C-C’).
This dynamic spatial and temporal expression pattern
suggests that Fezf2 transcription is under the control of
a complex regulatory program.
Identification of putative regulatory regions around the
Fezf2 locus
Recent work has identified several transcription factors
that are essential for cortical neuron fate specification
and differentiation. Among these, SOX5 and TBR1 ap-
pear to directly regulate Fezf2 transcription [22-24].
Using chromatin isolated from E15.5 mouse cortices, we
mapped the binding of transcription factors expressed in
L5 and L6 that were previously shown to be important
for cortical development. These included FOXG1, NFIB,
SOX5, and TBR1 [22-33]. We found that FOXG1,
SOX5, and TBR1 bound to the evolutionarily conservedFigure 1 Fezf2 is dynamically expressed during cortical development.
Fezf2 reveals its expression pattern during development. Ctx, cortex; LGE, la
eminence; PP, preplate; Str, striatum; VZ, ventricular zone. Scale bars: (A) 10region immediately upstream of Fezf2 (Figure 2B), sug-
gesting that this region may contain the Fezf2 promoter.
Interestingly, all of these factors bound to a previously
identified enhancer downstream of Fezf2, enhancer 434
(also known as E4) (Figure 2B). In addition to the up-
stream region and enhancer 434, FOXG1 and TBR1
bound a region in the neighboring Cadps gene, near the
5’ end of Fezf2 (Figure 2C). Taken together, our ChIP-
seq results indicate that multiple transcription factors
that are expressed in deep-layer neurons and are critical
for cortical development bind at or near the Fezf2 locus.
To determine the significance of our ChIP-seq data we
searched the VISTA Enhancer Browser (enhancer.lbl.
gov) for sequences in and near Fezf2 that may regulate
its expression [34]. This approach uncovered several en-
hancers around Fezf2. These included an enhancer at
the 5’ side of Fezf2, enhancer 1316, and the previously
studied enhancer at the 3’ side, enhancer 434 (Figure 2A).
Our ChIP-seq data demonstrated binding within or near
these enhancers, suggesting they are likely important for
regulating Fezf2 transcription within the cerebral cortex
(Figure 2B,C).
The 2.7 kb promoter is active across all Fezf2 expression
domains
Previous work identified the 2.7 kb region upstream of
and including the Fezf2 start codon as sufficient to drive
forebrain expression before the onset of cortical neuro-
genesis [35]. This region was bound by multiple transcrip-
tion factors in our ChIP-seq dataset (Figure 2B). We
generated stable transgenic lines expressing the LacZ re-
porter under the control of this 2.7 kb sequence to study
its activity throughout cortical development. When the
earliest-born cortical projection neurons were being gen-
erated at E11.5, we observed LacZ activity throughout the
cortex that mimicked endogenous Fezf2 expression (com-
pare Figure 3A with Figure 1A). We observed ß-gal ex-
pression in SOX2+ cortical progenitor cells and in TBR1+
and Tuj1+ postmitotic neurons (Figure 3B-D).In situ hybridization at E12.5 (A-A’), E15.5 (B-B’), and P0 (C-C’) for
teral ganglionic eminence; LV, lateral ventricle; MGE, medial ganglionic
0 μm, (A’) 10 μm, (B) 250 μm, (B’) 25 μm, (C) 500 μm, (C’) 50 μm.
Figure 2 Mapping of transcription factor binding around the Fezf2 locus. (A) Diagram of the Fezf2 locus indicating positions of the 2.7 kb
promoter and the putative enhancers 434, and 1316. (B, C) ChIP-seq was used to map the binding of transcription factors around the Fezf2 locus.
(B) An overview of binding around enhancer 434 and the upstream conserved region. (C) An overview of factor binding around enhancer 1316.
(B, C) Peaks called by MACS are highlighted in grey.
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mount X-Gal staining revealed expression throughout the
cerebral cortex in a high anterior-medial to low posterior-
lateral pattern (Figure 3E). However, unlike endogenous
Fezf2, which is expressed in the VZ and in deep cortical
layers (L5 and L6), the 2.7 kb-LacZ transgene was active
in all cortical layers (compare Figure 3F with Figure 1C).
LacZ was expressed in SOX2+ progenitor cells in the
VZ and in the CTIP2+ or SATB2+ projection neurons
(Figure 3G-I’). LacZ expression at P12 was similar to
that observed at P0 (Additional file 1). Taken together,
these results indicate that the 2.7 kb promoter is activethroughout cortical development and is sufficient to
drive transcription across all endogenous Fezf2 expression
domains (progenitor cells, L5 and L6 neurons). However,
its expression in upper cortical layers indicates that add-
itional cis-elements are required to properly coordinate
Fezf2 expression.
Enhancer 434 activity is strongest in cortical progenitor
cells
Previous work has shown that enhancer 434 is highly
conserved across vertebrate species and is necessary for
Fezf2 expression in the cortex [36]. Deletion of this
Figure 3 Promoter activity of the 2.7 kb fragment during cortical development. (A) X-Gal staining at E11.5 revealed reporter activity in the
cerebral cortex, similar to endogenous Fezf2 expression. (B-D) Immunohistochemistry with ß-Gal antibody combined with SOX2 (B), Tuj1 (C), and
TBR1 (D) antibodies. (E) Whole mount X-Gal staining of P0 brains demonstrating expression in the forebrain. (F) X-Gal staining of P0 brain sections.
(G-I’) Immunohistochemistry using ß-Gal antibody combined with antibodies for SOX2 (G, G’), CTIP2 (H, H’) and SATB2 (I, I’). Arrows represent
co-expression of LacZ and the indicated markers. Arrowheads indicate a lack of co-expression. PP, preplate. Scale bars: (A) 200 μm, (D) 50 μm,
(E) 250 mm, (F) 500 μm, (I) 100 μm, (I’) 50 μm.
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(BAC) containing a Fezf2-EGFP reporter or from its en-
dogenous locus resulted in a loss of EGFP or Fezf2 expres-
sion in the cerebral cortex [36]. However, it remains
unknown whether enhancer 434 alone is sufficient to pro-
mote Fezf2 expression in subcerebral projection neurons.Figure 4 Enhancer 434 is active in cortical progenitor cells. (A-C) Imm
E11.5 that co-expressed SOX2 (A), PAX6 (B) and PHH3 (C). LacZ was also e
(D). X-Gal staining of whole mount P0 brains (E) and sections (F) demonst
ß-Gal antibody combined with antibodies for RGC markers BLBP (G) and PA
cells were in GFAP+ astrocytes throughout the forebrain. A subset of non-astr
of LacZ and the indicated markers. Hip, hippocampus; WM, white matter.
(I) 500 μm, (J) 100 μm, (J’) 50 μm, (K) 25 μm.We generated stable transgenic lines expressing LacZ
under the control of enhancer 434 and the hsp68 min-
imal promoter [37]. At E11.5, ß-gal was expressed in
SOX2+ and PAX6+ cortical progenitor cells (Figure 4A-B),
including the metaphase cells that were labeled by
PHH3 antibody at the ventricular surface (Figure 4C).unohistochemistry demonstrated LacZ expression in progenitor cells at
xpressed in a few postmitotic neurons in the preplate marked by Tuj1
rated reporter activity in the VZ. (G, H) Immunohistochemistry using
X6 (H). (I, K, L) In adult animals, the majority of enhancer 434-LacZ+
ocyte like cells expressed SATB2 (J, J’). Arrows represent co-expression
Scale bars: (D) 50 μm, (E) 250 mm, (F) 500 μm, (G) 25 μm, (H) 10 μm,
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pressed ß-gal (Figure 4D). Whole mount staining of P0
brains revealed strong LacZ activity throughout multiple
brain regions (Figure 4E). However, the majority of enhan-
cer 434 activity was in the VZ of the cortex and basal gan-
glia (Figure 4F). Immunohistochemistry with antibodies
for LacZ and the radial glial cell (RGC) marker BLBP
demonstrated significant co-localization (Figure 4G). Add-
itionally, some LacZ+ cells in the VZ expressed the RGC
marker PAX6 (Figure 4H). Some cells in the cortical plate
expressed LacZ, however a minority of these LacZ+ cells
expressed the projection neuron markers SOX5 and
SATB2 (Additional file 2). Thus, at P0 enhancer 434 activ-
ity is strongest in cortical progenitor cells. This strong
LacZ signal observed in the VZ is consistent with the ac-
tivity of enhancer 434 reported by the VISTA Enhancer
Browser (enhancer.lbl.gov).
In adult mice, LacZ expression was observed in the
cerebral cortex, white matter, hippocampus, and stri-
atum (Figure 4I-L). Most of the LacZ+ cells exhibited
typical astrocyte-like morphology and expressed the
astrocyte marker GFAP (Figure 4K, L). A minority of
LacZ+ cells in the cerebral cortex expressed the cortical
projection neuron marker SATB2 (Figure 4J’). This shift
in enhancer 434 activity suggests that it may have diver-
gent functions during development versus in adult ani-
mals. Taken together, these data demonstrate that during
cortical development enhancer 434 activity is strongest
in progenitor cells, one of the endogenous expression
domains of Fezf2.Enhancer 1316 is active in deep-layer projection neurons
in the cerebral cortex
We next investigated the activity of enhancer 1316. MultiZ
alignment of this region showed strong vertebrate conserva-
tion, especially within the middle 500 bp (Additional file 3).
We generated stable transgenic lines expressing LacZ under
control of enhancer 1316 and the hsp68 minimal promoter.
At E11.5, ß-gal was present throughout the newly generated
preplate (Figure 5A), in Tuj1+ neurons (Figure 5D). LacZ+
cells did not express the progenitor cell markers PAX6 or
SOX2 (Figure 5B, C).
Whole mount staining at P0 revealed LacZ activity in
deep layers of the cerebral cortex (Figure 5E). LacZ was
expressed in the subplate and in some deep-layer neurons,
but not in cortical progenitors or astrocytes (Figure 5F).
Some LacZ+ cells expressed CTIP2 and SATB2 (Figure 5H-I’).
'None of the LacZ+ cells expressed SOX2 (Figure 5G,
G’). Analysis at P12 revealed a similar LacZ expres-
sion pattern to that observed at P0 (Additional file 4).
Taken together, these results indicate that within the
cerebral cortex, enhancer 1316 is strictly active in
deep-layer neurons.Discussion
We set out to understand how expression of Fezf2 is
spatially and temporally controlled during development of
the cerebral cortex. Previous work demonstrates that Fezf2
transcription levels are critically important for specifica-
tion of cortical projection neuron fates [13-17,22-24,31].
Our ChIP-seq data indicate that multiple transcription
factors that are expressed in deep-layer neurons bind to
evolutionarily conserved sequences around the Fezf2
locus. The large number of transcription factors that
bound enhancer 434 underscores its developmental im-
portance. Recent deletion analysis demonstrated that
this enhancer is critical for subcerebral projection neuron
identity and connectivity [36]. In the current study, the
majority of enhancer 434 activity during cortical neuro-
genesis was in progenitor cells, suggesting that this
element also functions to promote Fezf2 expression in
the VZ, one of the endogenous Fezf2 expression do-
mains (Figure 6).
An alternative interpretation of this result is that differ-
ent experimental strategies may account for the somewhat
distinct conclusions regarding the activity of enhancer
434. In the study by Shim et al. [36], enhancer 434 was de-
leted from either a bacterial artificial chromosome con-
taining a Fezf2-EGFP reporter or from its endogenous
genomic locus. In both cases, deletion of enhancer 434 re-
sulted in a loss of GFP or Fezf2 expression, respectively,
and failed extension of subcerebral projections. In the
present study, we assayed the activity of enhancer 434 in
isolation and found that it drove LacZ activity strongest in
progenitor cells with lower levels of reporter activity in
postmitotic neurons. These data indicate that when taken
out of its endogenous locus, enhancer 434 is sufficient to
drive reporter expression in the progenitor cells. It is im-
portant to note however that both the Shim et al. study
[36] and the data presented here indicate a critical role for
enhancer 434 in the regulation of Fezf2 transcription.
Although the present study identifies conserved regula-
tory elements around the Fezf2 locus, functional enhancer-
promoter interactions cannot be established based upon
transgenic reporter assays alone. Specifically, whether en-
hancer 1316 functionally interacts with the Fezf2 promoter
to regulate transcription remains unknown. Recently pub-
lished high throughput chromosome conformation cap-
ture (Hi-C) suggests an interaction between enhancer
1316 and the Fezf2 promoter [38]. However, this enhancer
does not appear to be essential for Fezf2 expression during
development. Transgenic mice containing a modified BAC
(RP23-141E17) that express EGFP or CRE from the Fezf2
open reading frame have been generated. Although enhan-
cer 1316 is not contained within this BAC, GFP, or CRE
expression in these transgenic mice recapitulates endogen-
ous Fezf2 gene expression [36,39,40], suggesting that this
enhancer is not essential for Fezf2 expression during
Figure 5 Enhancer 1316 is active in deep-layer cortical neurons. (A-D) Immunohistochemical analysis of E11.5 brain sections using
antibodies for ß-Gal (A), ß-Gal and PAX6 (B), ß-Gal and SOX2 (C), and ß-Gal and Tuj1 (D). (E, F) X-Gal staining of P0 whole mount brains (E) and
brain sections (F). (G-I) Immunohistochemistry using ß-Gal antibody combined with antibodies for SOX2 (G), CTIP2 (H), and SATB2 (I). Arrows
represent co-expression of LacZ and the indicated markers. Arrowheads indicate a lack of co-expression. Scale bars: (A) 200 μm, (D) 50 μm,
(E) 250 mm, (F) 500 μm, (I) 100 μm, (I’) 25 μm.
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(s) present on the RP23-141E17 BAC may function redun-
dantly with enhancer 1316 to promote Fezf2 expression in
deep layer neurons.
Multiple cis-regulatory sequences around Fezf2 exhi-
bited distinct yet overlapping activities during cortical de-
velopment. These results are similar to the regulation of
the eve gene locus in Drosophila where multiple, partiallyredundant enhancers control expression in individual
stripes along the anterior-posterior axis of the embryo
[41,42]. Ultimately, combined activity of these enhancers
is required to drive the precise spatio-temporal expression
of eve. Similar regulatory paradigms have also been uncov-
ered in mammals through analysis of the interferon-beta
[43] or Fgf8 [44] loci. In our study, neither of the identified
enhancers nor the 2.7 kb promoter, when assayed in
Figure 6 A model for the regulation of Fezf2 transcription in the cortex. The 2.7 kb promoter was sufficient to drive transcription across all
endogenous Fezf2 expression domains throughout development of the cerebral cortex. Enhancer 434 exhibited strongest activity in cortical
progenitor cells and in contrast enhancer 1316 was strictly active in deep-layer postmitotic neurons.
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http://www.neuraldevelopment.com/content/9/1/6isolation, were sufficient to drive LacZ reporter expres-
sion in an identical pattern to that of endogenous Fezf2
expression. This suggests the presence of an additional
enhancer (enhancers) that promotes high levels of
expression specifically in L5 neurons. Moreover, the
strong activity of the 2.7 kb promoter in upper cortical
layers indicates that repressor sequences are necessary
to restrict its activity to cortical progenitor cells and
deep-layer neurons. Identification of these regulatory
sequences combined with an increased understanding
of the chromatin environment surrounding the Fezf2
locus should help to shed light on the mechanisms that
precisely regulate its transcription.
We recently reported that in addition to deep-layer
cortical neurons, Fezf2 is expressed in progenitor cells
throughout cortical neurogenesis [39]. Phenotypic analysis
of Fezf2−/− mice indicates that it is required for both the
patterning and maintenance of forebrain progenitors [45],
and the fate specification of deep-layer cortical projection
neurons [13-16]. In Fezf2−/− mutant cortices, subcerebral
projection neurons switch their identity to become callosal
or corticothalamic projection neurons. However, it re-
mains unclear whether Fezf2 functions within cortical
progenitor cells, postmitotic neurons or a combination
of both in order to properly specify the fate of deep-
layer cortical projection neurons. Identifying distinct
promoter and enhancer sequences that regulate Fezf2
transcription may help provide answers to this question.
Conclusions
Given recent progress identifying putative mammalian en-
hancers [37], it is critical that we understand the spatial
and temporal activities of these sequences in the regula-
tion of individual genes, in order to appreciate the dele-
terious effects of mutations in non-coding sequences
identified through GWAS. Focusing on Fezf2, a key regu-
lator of cortical development and deep-layer projection
neuron fate, our study suggests that multiple enhancer
and promoter activities can coordinate gene expression
during brain development. Recent work indicates that
Fezf2 is expressed in neocortical progenitors throughout
development. Although mice lacking Fezf2 exhibit deve-
lopmental defects largely within deep-layer neurons (L5and L6), its role in cortical progenitors versus postmitotic
neurons remains unclear. Identifying the regulatory mech-
anisms that control Fezf2 transcription will enable the
functional dissection of its role within these distinct cellu-
lar populations. We propose that the combined activities
of the 2.7 kb promoter, enhancer 434, and possibly enhan-
cer 1316 constitute a cis-regulatory module that controls
Fezf2 in distinct domains of the cerebral cortex, ultimately
leading to its dynamic expression during cortical develop-
ment (Figure 6).
Methods
Animals
All experiments in this study were carried out in accordance
with protocols approved by the IACUC at the University of
California, Santa Cruz and were performed in accordance
with institutional and federal guidelines. The day of vaginal
plug detection was designated as embryonic day 0.5 (E0.5).
The day of birth was designated as postnatal day 0 (P0).
Transgenic mice were generated using standard protocols
[46]. To generate stable transgenic lines, founders were
outcrossed to CD1 wild-type females for a minimum of
three generations before analysis. Number of founder lines
generated: 2.7 kb-LacZ (2), enhancer 434-LacZ (3), enhan-
cer 1316-LacZ (4).
Plasmids
Generation of the 2.7 kb-lacZ plasmid was previously
described [35]. For enhancer 434-lacZ, the genomic re-
gion was obtained from mouse genomic DNA by PCR
using primers: ATCGCTCGAGCAGGCTGTAGGATGG
GCAGCAGGAGTTTC and ATCGAAGCTTGTAACA
AGTCAGGTGAGCAGGCGGTA. The product was then
cloned into the hsp68-lacZ expression vector using Gateway
cloning according to the manufacturer’s protocol [11].
Enhancer 1316-lacZ was generated from human genomic
DNA using primers AAACCACACAGCTGGTTTCC and
TTTCCCGATAGATCGTCAGC and cloned into the
hsp68-lacZ expression vector [37].
Histology
Immunostaining and in situ hybridization were performed
as previously described [47]. The Fezf2 cRNA probe
Eckler et al. Neural Development 2014, 9:6 Page 9 of 11
http://www.neuraldevelopment.com/content/9/1/6corresponds to nucleotides 644 to 1,374 of mouse Fezf2
(GenBank: NC_000080). LacZ staining was preformed
according to standard protocols. Primary antibodies used:
Chicken anti β-gal (Abcam, 1:500), Rabbit anti BLBP
(Millipore, 1:500), Rat anti CTIP2 (Abcam, 1:1,000), Guinea
Pig anti GFAP (Advaned Immuno Chemical, 1:100), Rabbit
anti PAX6 (Covance, 1:100), PHH3 (Cell Signaling, 1:100),
Rabbit anti SATB2 (Abcam, 1:1,000), Goat anti SOX2
(Santa Cruz Biotech, 1:500), Rabbit anti SOX5 (Abcam,
1:500), Rabbit anti TBR1 (Abcam, 1:1,000), Mouse anti
Tuj1 (Covance, 1:1,000). Primary antibodies were detected
using AlexaFluor-conjugated secondary antibodies (Invitro-
gen, 1:1,000). DNA was visualized with DAPI (1:50,000).
Microscopy
Bright field and epiflourescence images were captured on
an Olympus BX51 microscope using a Q Imaging Retiga
EXj camera or a Keyence BZ-9000 microscope. Confocal
images were captured on a Leica TCS SP5 confocal micro-
scope. Images were processed using Adobe Photoshop
CS5 to adjust brightness and contrast.
ChIP-Seq
Chromatin immunoprecipation was performed as previ-
ously described [24]. Antibodies used were Rabbit anti
FOXG1 (Cell Signaling), Rabbit anti NFIB (Active Motif),
Rabbit anti SOX5 (Abcam), and Rabbit anti TBR1 (Abcam).
Sequencing libraries were generated using the Illumina
TruSeq kit according to the manufacturer’s protocol.
Sequencing was performed on an Illumina Hiseq 2000
at the UCSC Genome Technology Center. Input DNA
was sequenced as control. Sequencing reads were mapped
to the mouse genome (mm9) using the Bowtie mapping
algorithm. Non-overlapping reads and PCR duplicates
were removed. Peaks were called using the MACS algo-
rithm [48].
Additional files
Additional file 1: 2.7 kb promoter activity at P12. (A) The activity of
the 2.7 kb promoter at P12 was similar to that observed at P0, with
expression throughout the cortex and the strongest activity in upper
layers. (B-C’) LacZ was expressed in some CTIP2+ and TBR1+ cells in deep
layers. (D, D’) However, the highest density of LacZ+ cells was in upper
layers cells that expressed SATB2. Panels B’-D’ show amplified areas
boxed in panels B-D, respectively. Arrows represent co-expression of LacZ
and the indicated markers. Arrowheads indicate a lack of co-expression.
Ctx, cortex; LV, lateral ventricle; Str, striatum. Scale bars: (a) 500 μm, (d)
100 μm, (d’) 50 μm.
Additional file 2: Enhancer 434 activity at P0. (A-B’) LacZ expression
was observed in a few post-mitotic neurons expressing SOX5 (A, A’) or
SATB2 (B, B’). A’ and B’ show amplified areas boxed in panels A and B.
Arrows represent co-expression of LacZ and the indicated markers.
Arrowheads indicate a lack of co-expression. Scale bars: (B) 100 μm, (B’) 50 μm.
Additional file 3: Vertebrate conservation of enhancer 1316. The
UCSC genome browser was used to perform Multiz alignment of
enhancer 1316 from 30 vertebrates. Strong conservation was mostevident within the middle 500 bp (approximately) of this region.
Basewise conservation is represented as greyscale darkness with higher
conservation corresponding to darker values. Gap Annotation: single line,
no bases in the aligned species; double line, aligning species has one or
more un-alignable bases in the gap region; red coloring, aligning species
has Ns in the gap region. Genomic Breaks: green square brackets, enclose
shorter alignments consisting of DNA from one genomic context in the
aligned species nested inside a larger chain of alignments from a different
genomic context.
Additional file 4: Activity of enhancer 1316 at P12. (A-D’) Expression
at P12 mirrored P0. (A) X-Gal staining. (B-D’) Immunohistochemistry
analysis of the brain sections. Some LacZ positive cells in deep layers
expressed CTIP2 (B-B’), SATB2 (C-C’), and TBR1 (D-D’). B’-D’ show enlargement
of areas boxed in panels B-D. Ctx, cortex; LV, lateral ventricle; Str, striatum.
Scale bars: (A) 500 μm, (D) 100 μm, (D’) 20 μm.Abbreviations
BAC: Bacterial artificial chromosome; ß-gal: ß-galactosidase; ChIP-seq: Chromatin
co-immunoprecipitation and high throughput DNA sequencing; E: Embryonic
day; GWAS: Genome-wide association study; L5: Layer 5; L6: Layer 6; P: Postnatal
day; PCR: Polymerase chain reaction; RGC: Radial glial cell; SCPN: Subcerebral
projection neurons; VZ: Ventricular zone.Competing interests
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